Intravenous Tranexamic Acid Versus IV Carbetocin in Abdominal Myomectomy

Cairo University153 enrolled

Overview

the aim of the present study is to compare safety and efficacy of intravenous tranexamic acid versus IV carbetocin in reducing blood loss during abdominal myomectomy: a randomized controlled trial

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

QUADRUPLE

Enrollment

153

Conditions

Myomectomy

Interventions

intravenous tranexamic acidDRUG

The tranexamic acid (TXA) group will receive a single bolus IV injection of 15 mg/kg of TXA 20 minutes before surgical incision

intravenous carbetocinDRUG

The carbetocin group will receive a single bolus IV injection of 100 mcg of carbetocin 20 minutes before surgical incision

placeboDRUG

the placebo group will be given a normal saline IV bolus 20 minutes before surgical incision

Eligibility

Sex: FEMALE

Medical Language ↔ Plain English

Inclusion Criteria: * women with symptomatic fibroids candidate for abdominal myomectomy with staging of myoma from (3 to 6) according to FIGO staging Exclusion Criteria: * women with Myoma FIGO staging (1,2,7 and 8) candidate for laparoscopic or hysteroscopic myomectomy, women with allergy or contraindications to carbetocin or tranexamic acid

Outcomes

Primary Outcomes

intraoperative blood loss

the intraoperative blood loss in ml will be estimated during the procedure

Time frame: one hour

Secondary Outcomes

need for blood transfusion

need for intraoperative or postoperative blood transfusion

Time frame: 24 hours

Central Contacts

AHMED SAMY

CONTACT

+201100681167 ahmedsamy8233@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.